1
|
Tambe S, Nag S, Pandya SR, Kumar R, Balakrishnan K, Kumar R, Kumar S, Amin P, Gupta PK. Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review. ACS Infect Dis 2024; 10:1871-1889. [PMID: 38829047 DOI: 10.1021/acsinfecdis.4c00010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2024]
Abstract
Leishmaniasis, one of the most overlooked tropical diseases, is a life-threatening illness caused by the parasite Leishmania donovani that is prevalent in underdeveloped nations. Over 350 million individuals in more than 90 different nations worldwide are at risk of contracting the disease, which has a current fatality rate of 50 000 mortalities each year. The administration of liposomal Amp B, pentavalent antimonials, and miltefosine are still considered integral components of the chemotherapy regimen. Antileishmanial medications fail to treat leishmaniasis because of their numerous drawbacks. These include inadequate effectiveness, toxicity, undesired side effects, drug resistance, treatment duration, and cost. Consequently, there is a need to overcome the limitations of conventional therapeutics. Nanotechnology has demonstrated promising outcomes in addressing these issues because of its small size and distinctive characteristics, such as enhanced bioavailability, lower toxicity, biodegradability, and targeted drug delivery. This review is an effort to highlight the recent progress in various nanodrug delivery systems (nDDSs) over the past five years for treating leishmaniasis. Although the preclinical outcomes of nDDSs have shown promising treatment for leishmaniasis, further research is needed for their clinical translation. Advancement in three primary priority domains─molecular diagnostics, clinical investigation, and knowledge dissemination and standardization─is imperative to propel the leishmaniasis field toward translational outcomes.
Collapse
Affiliation(s)
- Srushti Tambe
- Institute of Chemical Technology, Department of Pharmaceutical Sciences and Technology, Mumbai, Maharashtra 400019, India
| | - Sagnik Nag
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor 47500, Malaysia
| | - Shivani R Pandya
- Research and Development Cell & Parul Institute of Applied Sciences, Parul University, Vadodara, Gujarat 391760, India
| | - Rohit Kumar
- Centre for Development of Biomaterials and Department of Life Sciences, Sharda School of Basic Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh 201310, India
| | - Kalpana Balakrishnan
- Department of Biotechnology, K.S. Rangasamy College of Technology, Tiruchengode, Namakkal, Tamil Nadu 637215, India
| | - Ranvijay Kumar
- University Centre for Research and Development and Department of Mechanical Engineering, Chandigarh University, Mohali, Punjab 140413, India
| | - Sandeep Kumar
- Centre of Research Impact and Outcome, Chitkara University, Rajpura, Punjab 140401, India
| | - Purnima Amin
- Institute of Chemical Technology, Department of Pharmaceutical Sciences and Technology, Mumbai, Maharashtra 400019, India
| | - Piyush Kumar Gupta
- Centre for Development of Biomaterials and Department of Life Sciences, Sharda School of Basic Sciences and Research, Sharda University, Greater Noida, Uttar Pradesh 201310, India
- Department of Biotechnology, Graphic Era (Deemed to Be University), Dehradun, Uttarakhand 248002, India
| |
Collapse
|
2
|
Guerra RO, do Carmo Neto JR, da Silva PEF, Franco PIR, Barbosa RM, de Albuquerque Martins T, Costa-Madeira J, de Assunção TSF, de Oliveira CJF, Machado JR, Silva Teixeira LDA, Rodrigues WF, Júnior VR, Silva ACA, da Silva MV. Metallic nanoparticles and treatment of cutaneous leishmaniasis: A systematic review. J Trace Elem Med Biol 2024; 83:127404. [PMID: 38364464 DOI: 10.1016/j.jtemb.2024.127404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 01/22/2024] [Accepted: 01/29/2024] [Indexed: 02/18/2024]
Abstract
BACKGROUND Cutaneous leishmaniasis (LC) is an infectious vector-borne disease caused by parasites belonging to the genus Leishmania. Metallic nanoparticles (MNPs) have been investigated as alternatives for the treatment of LC owing to their small size and high surface area. Here, we aimed to evaluate the effect of MNPs in the treatment of LC through experimental, in vitro and in vivo investigations. METHODS The databases used were MEDLINE/ PubMed, Scopus, Web of Science, Embase, and Science Direct. Manual searches of the reference lists of the included studies and grey literature were also performed. English language and experimental in vitro and in vivo studies using different Leishmania species, both related to MNP treatment, were included. This study was registered in PROSPERO (CRD42021248245). RESULTS A total of 93 articles were included. Silver nanoparticles are the most studied MNPs, and L. tropica is the most studied species. Among the mechanisms of action of MNPs in vitro, we highlight the production of reactive oxygen species, direct contact of MNPs with the biomolecules of the parasite, and release of metal ions. CONCLUSION MNPs may be considered a promising alternative for the treatment of LC, but further studies are needed to define their efficacy and safety.
Collapse
Affiliation(s)
- Rhanoica Oliveira Guerra
- Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto, SP, Brazil
| | - José Rodrigues do Carmo Neto
- Department of Bioscience and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiania, Goiás, Brazil.
| | - Priscilla Elias Ferreira da Silva
- Post Graduation Course of Tropical Medicine and Infectology, Institute of Healthy Science´s, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Pablo Igor Ribeiro Franco
- Department of Bioscience and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiania, Goiás, Brazil
| | - Rafaela Miranda Barbosa
- Department of Basic and Applied Immunology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
| | - Tarcísio de Albuquerque Martins
- Post-Graduation Course of Healthy Science, Institute of Healthy Science, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Juliana Costa-Madeira
- Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirão Preto, SP, Brazil
| | - Thais Soares Farnesi de Assunção
- Post Graduation Course of Tropical Medicine and Infectology, Institute of Healthy Science´s, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | | | - Juliana Reis Machado
- Department of General Pathology, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Luciana de Almeida Silva Teixeira
- Department of Internal Medicine, Institute of Healthy Science, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Wellington Francisco Rodrigues
- Post-Graduation Course of Healthy Science, Institute of Healthy Science, Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Virmondes Rodrigues Júnior
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences, Brazil
| | - Anielle Christine Almeida Silva
- Laboratory of New Nanostructured and Functional Materials, Physics Institute, Federal University of Alagoas, Maceió, Alagoas, Brazil
| | - Marcos Vinicius da Silva
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences, Brazil.
| |
Collapse
|
3
|
Fattahian M, Ghanadian M, Zolfaghari B, Abdeyazdan S, Saberi S, Zulfiqar F, Khan IA, Ali Z. Phytochemical study of Seriphidium khorassanicum (syn. Artemisia khorassanica) aerial parts: sesquiterpene lactones with anti-protozoal activity. Nat Prod Res 2024; 38:16-27. [PMID: 35856479 DOI: 10.1080/14786419.2022.2102630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Accepted: 07/06/2022] [Indexed: 10/17/2022]
Abstract
Two new eudesmane-type sesquiterpene lactones, 1β,3α,8α-trihydroxy-11β,13-dihydroeudesma-4(15)-en-12,6α-olide (1) and 1β,4α,8α-trihydroxy-11β,13-dihydroeudesma-12,6α-olide (2), and an unprecedented elemane-type sesquiterpene lactone, 1β,2β,8α-trihydroxy-11β,13-dihydroelema-12,6α-olide (3) along with a known eudesmanolide artapshin (4) were isolated from Seriphidium khorassanicum. Structures were elucidated by NMR, HR-ESI-MS, and ECD spectral data analysis. The anti-protozoal activity was evaluated against Leishmania major promastigotes and amastigote-infected macrophages. They showed dose- and time-dependent activity against L. major amastigotes with IC50 values in the range of 4.9 to 25.3 μM being favourably far below their toxicity against normal murine macrophages with CC50 values ranging from 432.5 to 620.7 μM after 48 h of treatment. Compound 3 exhibited the strongest activity and the highest selectivity index (SI) with IC50 of 4.9 ± 0.6 μM and SI of 88.2 comparable with the standard drug, meglumine antimoniate (Glucantime), with IC50 and SI values of 15.5 ± 2.1 μM and 40.0, respectively.
Collapse
Affiliation(s)
- Maryam Fattahian
- School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mustafa Ghanadian
- School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
- Shahid Beheshti Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Behzad Zolfaghari
- School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Sara Abdeyazdan
- School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Sedigheh Saberi
- Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Fazila Zulfiqar
- National Center for Natural Products Research, University of Mississippi, MS, USA
| | - Ikhlas A Khan
- National Center for Natural Products Research, University of Mississippi, MS, USA
| | - Zulfiqar Ali
- National Center for Natural Products Research, University of Mississippi, MS, USA
| |
Collapse
|
4
|
Sherafati J, Dayer MS, Ghaffarifar F, Akbarzadeh K, Pirestani M. Evaluating leishmanicidal effects of Lucilia sericata products in combination with Apis mellifera honey using an in vitro model. PLoS One 2023; 18:e0283355. [PMID: 37535629 PMCID: PMC10399734 DOI: 10.1371/journal.pone.0283355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 03/07/2023] [Indexed: 08/05/2023] Open
Abstract
Leishmaniasis is a zoonotic disease caused by an intracellular parasite from the genus Leishmania. Lack of safe and effective drugs has increasingly promoted researches into new drugs of natural origin to cure the disease. The study, therefore, aimed to investigate the anti-leishmanial effects of Lucilia sericata larval excretion/secretion (ES) in combination with Apis mellifera honey as a synergist on Leishmania major using an in vitro model. Various concentrations of honey and larval ES fractions were tested against promastigotes and intracellular amastigotes of L. major using macrophage J774A.1 cell line. The inhibitory effects and cytotoxicity of ES plus honey were evaluated using direct counting method and MTT assay. To assess the effects of larval ES plus honey on the amastigote form, the rate of macrophage infection and the number of amastigotes per infected macrophage cell were estimated. The 50% inhibitory concentration (IC50) values were 21.66 μg/ml, 43.25 60 μg/ml, 52.58 μg/ml, and 70.38 μg/ml for crude ES plus honey, ES >10 kDa plus honey, ES <10 kDa plus honey, and honey alone, respectively. The IC50 for positive control (glucantime) was 27.03 μg/ml. There was a significant difference between viability percentages of promastigotes exposed to different doses of applied treatments compared to the negative control (p≤ 0.0001). Microscopic examination of amastigote forms revealed that dosages applied at 150 to 300 μg/ml significantly reduced the rate of macrophage infection and the number of amastigotes per infected macrophage cell. Different doses of larval products plus honey did not show a significant toxic effect agaist macrophage J774 cells. The larval ES fractions of L. sericata in combination with A. mellifera honey acted synergistically against L. major.
Collapse
Affiliation(s)
- Jila Sherafati
- Faculty of Medical Sciences, Department of Parasitology and Medical Entomology, Tarbiat Modares University, Tehran, Iran
- Faculty of Medical Sciences, Student Research Committee, Tarbiat Modares University, Tehran, Iran
| | - Mohammad Saaid Dayer
- Faculty of Medical Sciences, Department of Parasitology and Medical Entomology, Tarbiat Modares University, Tehran, Iran
| | - Fatemeh Ghaffarifar
- Faculty of Medical Sciences, Department of Parasitology and Medical Entomology, Tarbiat Modares University, Tehran, Iran
| | - Kamran Akbarzadeh
- Department of Medical Entomology and Vector Control, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
| | - Majid Pirestani
- Faculty of Medical Sciences, Department of Parasitology and Medical Entomology, Tarbiat Modares University, Tehran, Iran
| |
Collapse
|
5
|
Xu J, Wang F, Zhan J, Li Y, Wang T, Ma R, Tian Y. Construction of TiO2/starch nanocomposite cryogel for ethylene removal and banana preservation. Carbohydr Polym 2023; 312:120825. [PMID: 37059552 DOI: 10.1016/j.carbpol.2023.120825] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 02/24/2023] [Accepted: 03/14/2023] [Indexed: 03/31/2023]
Abstract
Perishability caused by natural plant hormone ethylene has attracted great attention in the field of fruit and vegetable (F&V) preservation. Various physical and chemical methods have been applied to remove ethylene, but the eco-unfriendliness and toxicity of these methods limit their application. Herein, a novel starch-based ethylene scavenger was developed by introducing TiO2 nanoparticles into starch cryogel and applying ultrasonic treatment to further improve ethylene removal efficiency. As a porous carrier, the pore wall of cryogel provided dispersion space, which increased the area of TiO2 exposed to UV light, thereby endowing starch cryogel with ethylene removal capacity. The photocatalytic performance of scavenger reached the maximum ethylene degradation efficiency of 89.60 % when the TiO2 loading was 3 %. Ultrasonic treatment interrupted starch molecular chains and then promoted their rearrangement, increasing the material specific surface area from 54.6 m2/g to 225.15 m2/g and improving the ethylene degradation efficiency by 63.23 % compared with the non-sonicated cryogel. Furthermore, the scavenger exhibits good practicability for removing ethylene as a banana package. This work provides a new carbohydrate-based ethylene scavenger, utilizing as a non-food contact inner filler of F&V packaging in practical applications, which exhibits great potential in F&V preservation and broadens the application fields of starch.
Collapse
|
6
|
Registre C, Soares RDOA, Rubio KTS, Santos ODH, Carneiro SP. A Systematic Review of Drug-Carrying Nanosystems Used in the Treatment of Leishmaniasis. ACS Infect Dis 2023; 9:423-449. [PMID: 36795604 DOI: 10.1021/acsinfecdis.2c00632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Leishmaniasis is an infectious disease responsible for a huge rate of morbidity and mortality in humans. Chemotherapy consists of the use of pentavalent antimonial, amphotericin B, pentamidine, miltefosine, and paromomycin. However, these drugs are associated with some drawbacks such as high toxicity, administration by parenteral route, and most seriously the resistance of some strains of the parasite to them. Several strategies have been used to increase the therapeutic index and reduce the toxic effects of these drugs. Among them, the use of nanosystems that have great potential as a site-specific drug delivery system stands out. This review aims to compile results from studies that were carried out using first- and second-line antileishmanial drug-carrying nanosystems. The articles referred to here were published between 2011 and 2021. This study shows the promise of effective applicability of drug-carrying nanosystems in the field of antileishmanial therapeutics, with the perspective of providing better patient adherence to treatment, increased therapeutic efficacy, reduced toxicity of conventional drugs, as well as the potential to efficiently improve the treatment of leishmaniasis.
Collapse
Affiliation(s)
- Charmante Registre
- Phytotechnology Laboratory, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Minas Gerais 35400000, Brazil
| | - Rodrigo D O A Soares
- Immunopathology Laboratory, Research Center in Biological Sciences/NUPEB, Federal University of Ouro Preto, Ouro Preto, Minas Gerais 35400000, Brazil
| | - Karina T S Rubio
- Toxicology Laboratory, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Minas Gerais 35400000, Brazil
| | - Orlando D H Santos
- Phytotechnology Laboratory, School of Pharmacy, Federal University of Ouro Preto, Ouro Preto, Minas Gerais 35400000, Brazil
| | - Simone P Carneiro
- Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany
| |
Collapse
|
7
|
Abpeikar Z, Safaei M, Akbar Alizadeh A, Goodarzi A, Hatam G. The novel treatments based on tissue engineering, cell therapy and nanotechnology for cutaneous leishmaniasis. Int J Pharm 2023; 633:122615. [PMID: 36657555 DOI: 10.1016/j.ijpharm.2023.122615] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 01/09/2023] [Accepted: 01/11/2023] [Indexed: 01/18/2023]
Abstract
Cutaneous leishmaniasis (CL) is a global public health issue. Conventional treatments have substantial costs, side effects, and parasite resistance. Due to easy application and inexpensive cost, topical treatment is the optimal approach for CL. It could be used alone or with systemic treatments. Electrospun fibers as drug release systems in treating skin lesions have various advantages such as adjustable drug release rate, maintaining appropriate humidity and temperature, gas exchange, plasticity at the lesion site, similarity with the skin extracellular matrix (ECM) and drug delivery with high efficiency. Hydrogels are valuable scaffolds in the treatment of skin lesions. The important features of hydrogels include preserving unstable drugs from degradation, absorption of wound secretions, high biocompatibility, improving the re-epithelialization of the wound and preventing the formation of scars. One of the issues in local drug delivery systems for the skin is the low permeability of drugs in the skin. Polymeric scaffolds that are designed as microneedle patches can penetrate the skin and overcome this challenge. Also, drug delivery using nanocarriers increases the effectiveness of drugs in lower and more tolerable doses and reduces the toxicity of drugs. The application of cell therapy in the treatment of parasitic and infectious diseases has been widely investigated. The complexity of leishmaniasis treatment requires identifying new treatment options like cell therapy to overcome the disease. Topics investigated in this study include drug delivery systems based on tissue engineering scaffolds, nanotechnology and cell therapy-based studies to reduce the complications of CL.
Collapse
Affiliation(s)
- Zahra Abpeikar
- Department of Tissue Engineering, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
| | - Mohsen Safaei
- Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
| | - Ali Akbar Alizadeh
- Department of Tissue Engineering and Applied Cell Sciences, School of Advanced Medical Science and Technology, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Arash Goodarzi
- Department of Tissue Engineering, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran; Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran
| | - Gholamreza Hatam
- Basic Sciences in Infectious Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
| |
Collapse
|
8
|
Abdeyazdan S, Mohajeri M, Saberi S, Mirzaei M, Ayatollahi SA, Saghaei L, Ghanadian M. Sb(V) Kaempferol and Quercetin Derivative Complexes: Synthesis, Characterization and Antileishmanial Activities. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR 2022; 21:e128379. [PMID: 36942069 PMCID: PMC10024330 DOI: 10.5812/ijpr-128379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 08/14/2022] [Accepted: 08/15/2022] [Indexed: 11/16/2022]
Abstract
Background Recent studies on Leishmaniasis treatment have confirmed the antiparasitic effects of flavonols and organic antimony pentavalent [(Sb(V)] complexes. Objectives This study aimed to identify new Sb(V) complexes by combining the benefits of antimonials and flavonols as well as by optimizing their properties. Methods Kaempferol and quercetin peracetate were prepared using acetic anhydride in pyridine. By performing regioselective synthesis, 7-O-paramethylbenzyl as an electron-donating group and 7-O-paranitrobenzyl as an electron-withdrawing group were added to quercetin, and, then, the synthesis of Sb(V) kaempferol and quercetin derivative complexes were performed using SbCl5 solution in glacial acetic acid. The structures were confirmed by UV, ESI mass, IR, 1H-, and 13C-NMR spectral data, and the Stoichiometry of the ligand-metal complex by the mole ratio method. Computational molecular modeling was conducted using the Gaussian program. Results The structures were confirmed based on the results from UV, nuclear magnetic resonance (NMR), and electrospray ionization (ESI) mass analyses (3-12). Among the produced compounds, 11 and 12 as newly described, and other compounds as pre-defined compounds were identified. According to the results from biological test, kaempferol triacetate with more lipophilicity showed the highest anti-promastigote activity with an IC50 value of 14.93 ± 2.21 µM. As for anti-amastigote activity, despite the differences, all antimony complexes showed anti-amastigote effects in vitro with IC50 values of 0.52 to 14.50 µM. Conclusions All flavonol Sb(V) complexes showed higher activity compared to meglumine antimonate in anti-amastigote effect. Inside the host macrophages, by breaking down the complex into antimony and quercetin or kaempferol analogs, the observed antiparasitic effects may have been related to both Sb(V)/Sb(III) conversion and flavonoid antileishmanial activities.
Collapse
Affiliation(s)
- Sara Abdeyazdan
- Department of Pharmacognosy, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
- Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Maryam Mohajeri
- Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sedigheh Saberi
- Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mahmoud Mirzaei
- Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Seyed Abdulmajid Ayatollahi
- Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Department of Pharmacognosy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Lotfollah Saghaei
- Department of Medicinal Chemistry, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mustafa Ghanadian
- Department of Pharmacognosy, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran
- Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Corresponding Author: Department of Pharmacognosy, Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
| |
Collapse
|
9
|
Gürbüz Çolak N, Çetin Uyanikgil EÖ, Özbel Y, Töz S. The Designing of a Gel Formulation with Chitosan Polymer Using Liposomes as Nanocarriers of Amphotericin B for a Non-invasive Treatment Model of Cutaneous Leishmaniasis. Acta Parasitol 2022; 67:1354-1363. [PMID: 35857275 DOI: 10.1007/s11686-022-00594-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 07/01/2022] [Indexed: 11/27/2022]
Abstract
PURPOSE Leishmaniasis is a disease caused by different Leishmania spp., which are transmitted to humans by a bite of infected female sand flies. Cutaneous leishmaniasis (CL, oriental sore), visceral leishmaniasis (VL), and mucocutaneous leishmaniasis (MCL) are three main clinical forms, however, only CL and VL are seen in Turkey. Cutaneous leishmaniasis is characterized by skin lesion(s) and is one of the most important vector-borne diseases in Turkey with over 2000 cases reported annually in 40 out of 81 provinces. The treatment is usually made invasively and painfully by intralesional injection of pentavalent antimony compounds. Non-invasive and innovative treatment methods are needed as aimed in this study. METHODS In the present study, one of the classical antileishmanial drugs, amphotericin B (AmB), encapsulated in liposomes was evaluated using non-invasive design based on chitosan, which is a nontoxic, biocompatible and biodegradable polymer. To avoid the invasive effect of conventional intralesional needle application, the drug was encapsulated in liposomes and incorporated into a chitosan gel for applying topically on the skin lesion. The efficacy of encapsulation of amphotericin B into liposomes and the drug release from liposomes were studied. The chitosan gel was evaluated for viscosity, flowability, appearance and pH. The efficacy of the drug embedded into chitosan gel, liposomal AmB alone and chitosan gel alone in four different concentrations was also tested using Leishmania spp. promastigotes in vitro. RESULTS The findings have shown that AmB was encapsulated into the liposomes with high efficiency (86.6%) and long-term physical and chemical stability. Therefore, designed liposomal formulation was suitable for sustained release. The appearance of the drug-embedded chitosan gel was transparent and appropriate. Chitosan gels showed non- Newtonian behavior and plastic flow. The liposomal AmB also showed higher efficacy with no parasites in all concentrations while drug embedded into chitosan gel and chitosan gel alone were effective in two higher concentrations. The lower efficacy of the drug-embedded chitosan gel in 24 h in in-vitro study was probably due to slow release of the drug. CONCLUSION The gel design created in this study will provide ease of use for the lesions of CL patients that do not have a specific number, size, and shape. Follow-up studies by the ex-vivo macrophage infection model with Leishmania intracellular amastigote forms and Leishmania-infected animal models are needed to understand the present design's efficacy better.
Collapse
Affiliation(s)
- Nergiz Gürbüz Çolak
- Department of Molecular Biology and Genetics, Izmir İnstitute of Technology, Urla, Izmir, Turkey
| | - Emel Öykü Çetin Uyanikgil
- Faculty of Pharmacy, Department of Pharmaceutical Technology, Ege University, Bornova, Izmir, Turkey
| | - Yusuf Özbel
- Faculty of Medicine, Department of Parasitology, Ege University, Bornova, Izmir, Turkey
| | - Seray Töz
- Faculty of Medicine, Department of Parasitology, Ege University, Bornova, Izmir, Turkey.
| |
Collapse
|
10
|
Ładniak A, Jurak M, Wiącek AE. The effect of chitosan/TiO 2/hyaluronic acid subphase on the behaviour of 1,2-dioleoyl-sn-glycero-3-phosphocholine membrane. BIOMATERIALS ADVANCES 2022; 138:212934. [PMID: 35913237 DOI: 10.1016/j.bioadv.2022.212934] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Revised: 05/09/2022] [Accepted: 05/21/2022] [Indexed: 06/15/2023]
Abstract
The main aim of the study was to determine the effect of two polysaccharides: chitosan (Ch) and hyaluronic acid (HA), and/or titanium dioxide (TiO2) on the structure and behaviour of the 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) membrane. To achieve this goal the surface pressure as a function of the area per molecule (π-A) isotherm for the phospholipid monolayer was recorded. The shape of the π-A isotherms and compression-decompression cycles, as well as the compression modulus values, were analysed in terms of biocompatibility. Besides, morphology and thickness of the phospholipid layers obtained by means of Brewster angle microscope at different π, were determined. The obtained results show that both polysaccharides Ch, HA, as well inorganic TiO2 affect slightly the structure of the DOPC monolayer but do not disrupt it. Their presence brings no typical arrangements of both the polar heads and tails of DOPC molecules at the interface.
Collapse
Affiliation(s)
- Agata Ładniak
- Institute of Chemical Sciences, Department of Interfacial Phenomena, Faculty of Chemistry, Maria Curie-Skłodowska University, M. Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland; Laboratory of X-ray Optics, Department of Chemistry, Institue of Biology Sciences, Faculty of Science and Health, The John Paul II Catholic University of Lublin, Konstantynów 1J, 20-708 Lublin, Poland.
| | - Małgorzata Jurak
- Institute of Chemical Sciences, Department of Interfacial Phenomena, Faculty of Chemistry, Maria Curie-Skłodowska University, M. Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland
| | - Agnieszka E Wiącek
- Institute of Chemical Sciences, Department of Interfacial Phenomena, Faculty of Chemistry, Maria Curie-Skłodowska University, M. Curie-Skłodowska Sq. 3, 20-031 Lublin, Poland
| |
Collapse
|
11
|
Rezaei AR, Saberi S, Sepehri S. Synthesis, Antileishmanial Activity and Molecular Docking Study of a Series of Dihydropyridine Derivatives. Polycycl Aromat Compd 2022. [DOI: 10.1080/10406638.2022.2092877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- Ali-Reza Rezaei
- Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Sedigheh Saberi
- Department of Mycology and Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, I.R. Iran
| | - Saghi Sepehri
- Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
- Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| |
Collapse
|
12
|
Sherafati J, Dayer MS, Ghaffarifar F. Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions. Parasit Vectors 2022; 15:212. [PMID: 35710519 PMCID: PMC9204886 DOI: 10.1186/s13071-022-05322-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2021] [Accepted: 05/13/2022] [Indexed: 12/05/2022] Open
Abstract
BACKGROUND Leishmaniasis is a neglected infectious disease caused by protozoa of the genus Leishmania. The disease generally manifests as characteristic skin lesions which require lengthy treatment with antimonial drugs that are often associated with adverse side effects. Therefore, a number of studies have focused on natural compounds as promising drugs for its treatment. This study aimed to evaluate the effects of larval excretion/secretion products (ES) of Lucilia sericata in crude and fractionated forms on Leishmania major, by using in vitro and in vivo models. METHODS The in vitro experiments involved evaluation of ES on both promastigotes and macrophage-engulfed amastigotes, whereas the in vivo experiments included comparative treatments of skin lesions in L. major-infected mice with Eucerin-formulated ES and Glucantime. RESULTS The half maximal inhibitory concentrations of the crude ES, > 10-kDa ES fraction, < 10-kDa ES fraction, and Glucantime were 38.7 μg/ml, 47.6 μg/ml, 63.3 μg/ml, and 29.1 μg/ml, respectively. Significant differences were observed between percentage viabilities of promastigotes treated with the crude ES and its fractions compared with the negative control (P < 0.0001). The crude ES was more effective on amastigotes than the two ES fractions at 300 μg/ml. The macroscopic measurements revealed that the reduction of lesion size in mice treated with the crude ES followed quicker cascades of healing than that of mice treated with Glucantime and the ES fractions. CONCLUSIONS The present study showed that the larval ES of L. sericata in both crude and fractionated forms are effective for both intracellular and extracellular forms of L. major. Also, the ES exert both topical and systemic effects on mice experimentally infected with L. major.
Collapse
Affiliation(s)
- Jila Sherafati
- Department of Parasitology and Medical Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Jalal AleAhmad Highway, Nasr, P.O. Box 14115-111, Tehran, Islamic Republic of Iran
| | - Mohammad Saaid Dayer
- Department of Parasitology and Medical Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Jalal AleAhmad Highway, Nasr, P.O. Box 14115-111, Tehran, Islamic Republic of Iran
| | - Fatemeh Ghaffarifar
- Department of Parasitology and Medical Entomology, Faculty of Medical Sciences, Tarbiat Modares University, Jalal AleAhmad Highway, Nasr, P.O. Box 14115-111, Tehran, Islamic Republic of Iran
| |
Collapse
|
13
|
Goonoo N, Laetitia Huët MA, Chummun I, Karuri N, Badu K, Gimié F, Bergrath J, Schulze M, Müller M, Bhaw-Luximon A. Nanomedicine-based strategies to improve treatment of cutaneous leishmaniasis. ROYAL SOCIETY OPEN SCIENCE 2022; 9:220058. [PMID: 35719886 PMCID: PMC9198523 DOI: 10.1098/rsos.220058] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/16/2022] [Accepted: 04/14/2022] [Indexed: 05/03/2023]
Abstract
Nanomedicine strategies were first adapted and successfully translated to clinical application for diseases, such as cancer and diabetes. These strategies would no doubt benefit unmet diseases needs as in the case of leishmaniasis. The latter causes skin sores in the cutaneous form and affects internal organs in the visceral form. Treatment of cutaneous leishmaniasis (CL) aims at accelerating wound healing, reducing scarring and cosmetic morbidity, preventing parasite transmission and relapse. Unfortunately, available treatments show only suboptimal effectiveness and none of them were designed specifically for this disease condition. Tissue regeneration using nano-based devices coupled with drug delivery are currently being used in clinic to address diabetic wounds. Thus, in this review, we analyse the current treatment options and attempt to critically analyse the use of nanomedicine-based strategies to address CL wounds in view of achieving scarless wound healing, targeting secondary bacterial infection and lowering drug toxicity.
Collapse
Affiliation(s)
- Nowsheen Goonoo
- Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research, University of Mauritius, Réduit 80837, Mauritius
| | - Marie Andrea Laetitia Huët
- Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research, University of Mauritius, Réduit 80837, Mauritius
| | - Itisha Chummun
- Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research, University of Mauritius, Réduit 80837, Mauritius
| | - Nancy Karuri
- Department of Chemical Engineering, Dedan Kimathi University of Technology, Private Bag 10143 – Dedan Kimathi, Nyeri, Kenya
| | - Kingsley Badu
- Vector-borne Infectious Disease Group, Theoretical and Applied Biology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana
| | - Fanny Gimié
- Animalerie, Plateforme de recherche CYROI, 2 rue Maxime Rivière, 97490 Sainte Clotilde, Ile de La Réunion, France
| | - Jonas Bergrath
- Department of Natural Sciences, University of Applied Sciences Bonn-Rhein-Sieg, Heisenbergstrasse 16, D-53359 Rheinbach, Germany
| | - Margit Schulze
- Department of Natural Sciences, University of Applied Sciences Bonn-Rhein-Sieg, Heisenbergstrasse 16, D-53359 Rheinbach, Germany
| | - Mareike Müller
- Physical Chemistry I & Research Center of Micro- and Nanochemistry and (Bio)Technology (Cμ), Department of Chemistry and Biology, University of Siegen, Adolf-Reichwein-Strasse 2, 57076 Siegen, Germany
| | - Archana Bhaw-Luximon
- Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research, University of Mauritius, Réduit 80837, Mauritius
| |
Collapse
|
14
|
Synthesis and Biological Evaluation of Tetrahydropyrimidine and Dihydropyridine Derivatives Against Leishmania Major. Acta Parasitol 2022; 67:255-266. [PMID: 34279776 DOI: 10.1007/s11686-021-00457-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Accepted: 07/08/2021] [Indexed: 10/20/2022]
Abstract
PURPOSE A number of tetrahydropyrimidines and their bioisosteric dihydropyridines bearing chloro substituent at various positions of phenyl ring in C4 of main scaffolds were designed, synthesized and evaluated for antileishmanial activity. METHODS The antileishmanial activity of the synthesized compounds was evaluated against promastigote and amastigote forms. Moreover, molecular docking studies of the compounds in pteridine reductase 1 (PTR1) pocket were carried out to describe the results of biological experiments. RESULTS The compounds exhibited moderate to good antileishmanial activity against promastigote and amastigote forms. Among the screened compounds, 1d and 2c were found as the most potent compounds against promastigote form with EC50 values of 15.5 and 10.5 µM, respectively. Compounds 2a and 2c were the most potent compounds against amastigote form with EC50 values of 5.4 and 2.2 µM, respectively. CONCLUSION According to structure-activity relationship (SAR) studies, the chloro substituent in different positions of phenyl ring at C4 of 1,2,3,4-tetrahydropyrimidine (THPM) and 1,4-dihydropyridine (DHP) rings and also the length of the chain belonging to the ester groups could be important for antileishmanial activity of these compounds. Most of these compounds exhibited low cytotoxicity against macrophages. Compounds 1 h, 2a, 2b and 2c revealed higher activity than glucantime while all compounds showed lower activity toward amphotericine B. Docking studies showed that the synthesized compounds were fit well in the PTR1 pocket. Compounds 1 h and 2c indicated the highest score docking among screened compounds in PTR1 enzyme.
Collapse
|
15
|
Guerra RO, do Carmo Neto JR, de Albuquerque Martins T, Farnesi-de-Assunção TS, Junior VR, de Oliveira CJF, Silva ACA, da Silva MV. Metallic Nanoparticles: A New Frontier in the Fight Against Leishmaniasis. Curr Med Chem 2022; 29:4547-4573. [DOI: 10.2174/0929867329666220225111052] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 12/29/2021] [Accepted: 01/01/2022] [Indexed: 11/22/2022]
Abstract
Abstract:
Leishmaniasis is a cutaneous, mucocutaneous, or visceral parasitic disease caused by protozoa of the Leishmania genus. According to the World Health Organization, Leishmaniasis causes approximately 20–40 thousand deaths annually, and Brazil, India, and some countries in Africa are the most affected by this neglected disease. In addition to parasite’s ability to evade the host’s immune system, the incidence of vectors, the genetics of different hosts, and the large number of deaths are mainly due to failures in conventional treatments that have high toxicity, low effectiveness, and prolonged therapeutic regimens. Thus, the development of new alternative therapeutics with more effective and safer actions has become one of the main challenges for researchers studying leishmaniasis. Among the many research and tested options, metallic nanoparticles, such as gold, silver, zinc oxide, and titanium dioxide, have been shown to be one of the most promising therapeutic tool because they are easily prepared and chemically modified, have a broad spectrum of action, low toxicity, and can generate reactive oxygen species and other immune responses that favor their use against different species of Leishmania. This review explores the progress of the use of metallic nanoparticles as a new tool in the treatment of leishmaniasis, as well as discusses the gaps in knowledge that need to be addressed to consolidate a safe, effective, and definitive therapeutic intervention against these infections.
Collapse
Affiliation(s)
- Rhanoica Oliveira Guerra
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - José Rodrigues do Carmo Neto
- Department of Bioscience and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, GO, Brazil
| | - Tarcísio de Albuquerque Martins
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Thaís Soares Farnesi-de-Assunção
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Virmondes Rodrigues Junior
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Carlo José Freire de Oliveira
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| | - Anielle Christine Almeida Silva
- Laboratório de Novos Materiais Nanoestruturados e Funcionais (LNMIS), Physics Institute, Federal University of Alagoas, Maceió, Alagoas, Brazil
| | - Marcos Vinicius da Silva
- Department of Microbiology, Immunology and Parasitology, Institute of Biological and Natural Sciences of Federal University of Triângulo Mineiro, Uberaba, Minas Gerais, Brazil
| |
Collapse
|
16
|
Want MY, Yadav P, Khan R, Chouhan G, Islamuddin M, Aloyouni SY, Chattopadhyay AP, AlOmar SY, Afrin F. Critical Antileishmanial in vitro Effects of Highly Examined Gold Nanoparticles. Int J Nanomedicine 2021; 16:7285-7295. [PMID: 34737566 PMCID: PMC8560327 DOI: 10.2147/ijn.s268548] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Accepted: 09/15/2021] [Indexed: 11/23/2022] Open
Abstract
Introduction The current therapeutic armory for visceral leishmaniasis (VL) caused by Leishmania donovani complex is inadequate, coupled with serious limitations. Combination therapy has proved ineffective due to mounting resistance; however, the search for safe and effective drugs is desirable, in the absence of any vaccine. There is a growing interest in the application of nanoparticles for the therapeutic effectiveness of leishmaniasis. Aimed in this direction, we assessed the antileishmanial effect of gold nanoparticles (GNP) against L. donovani in vitro. Methods GNP were synthesized and characterized for particle size by dynamic light scattering (DLS) and atomic force microscopy (AFM) and for optical properties by UV-visible spectroscopy. Cytotoxicity of GNP was measured by the MTT proliferation assay. The antileishmanial activity of the nanoparticles was evaluated against L. donovani promastigotes and macrophage-infected amastigotes in vitro. Results GNP showed a strong SPR peak at 520 nm and mean particle size, polydispersity index (PDI), and zeta potential of 56.0 ± 10 nm, 0.3 ± 0.1 and −27.0 ± 3 mV, respectively. The GNPs were smooth and spherical with a mean particle diameter of 20 ± 5 nm. Nanoparticles [1.2–100 µM] did not reveal any cytotoxicity on RAW 264.7 murine macrophage cell line, but exerted significant activity against both promastigotes and amastigote stages of L. donovani with 50% inhibitory concentrations (IC50) of 18.4 ± 0.4 µM and 5.0 ± 0.3 µM, respectively. GNP showed significant antileishmanial activity with deformed morphology of parasites and the least number of surviving promastigotes after growth reversibility analysis. Conclusion GNP may provide a platform to conjugate antileishmanial drugs onto the surface of nanoparticles to enhance their therapeutic effectiveness against VL. Further work is warranted, involving more in-depth mechanistic studies and in vivo investigations.
Collapse
Affiliation(s)
- Muzamil Yaqub Want
- Parasite Immunology Laboratory, Department of Biotechnology, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.,Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA
| | - Priya Yadav
- Parasite Immunology Laboratory, Department of Biotechnology, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.,Department of Microbiology, University of Kalyani, Kalyani, West Bengal, 741235, India
| | - Rakin Khan
- Parasite Immunology Laboratory, Department of Biotechnology, Jamia Hamdard (Hamdard University), New Delhi, 110062, India
| | - Garima Chouhan
- Parasite Immunology Laboratory, Department of Biotechnology, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.,Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, Uttar Pradesh, 201306, India
| | - Mohammad Islamuddin
- Parasite Immunology Laboratory, Department of Biotechnology, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.,Molecular Virology and Vaccinology Laboratory, Department of Biotechnology, Jamia Millia Islamia, New Delhi, 110025, India
| | - Sheka Yagub Aloyouni
- Health Sciences Research Center, Princess Nourah Bint Abdulrahman University, Riyadh, 11671, Saudi Arabia
| | | | - Suliman Yousef AlOmar
- Doping Research Chair, Department of Zoology, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia
| | - Farhat Afrin
- Parasite Immunology Laboratory, Department of Biotechnology, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.,Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Taibah University, Madina, 41477, Saudi Arabia
| |
Collapse
|
17
|
Pereira MB, Sydor BG, Memare KG, Verzignassi Silveira TG, Alessi Aristides SM, Dalmarco EM, Vieira Teixeira JJ, Campana Lonardoni MV, Demarchi IG. In vivo efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: a systematic review. Nanomedicine (Lond) 2021; 16:1505-1518. [PMID: 34189952 DOI: 10.2217/nnm-2021-0119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/09/2022] Open
Abstract
Background: Nanotechnology is a promising strategy to improve existing antileishmanial agents. Objective: To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models. Materials & methods: The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting of In Vivo Experiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations. Results: Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice against Leishmania major, L. tropica or L. amazonensis. Limitations: Few studies were found to meet the eligibility criteria. Conclusion: All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies. Registration: PROSPERO register CRD42020170191.
Collapse
Affiliation(s)
- Meliana Borilli Pereira
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Bruna Gomes Sydor
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Karla Gabriela Memare
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Thaís Gomes Verzignassi Silveira
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Sandra Mara Alessi Aristides
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Eduardo Monguilhott Dalmarco
- Health Sciences Center - Department of Clinical Analysis, Federal University of Santa Catarina, Campus Universitário Reitor João David Ferreira Lima, s/n°, Bairro Trindade, Florianópolis, 88040-900, SC, Brazil
| | - Jorge Juarez Vieira Teixeira
- Department of Clinical Analysis & Biomedicine, State University Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil.,Post Graduation Program in Bioscience & Physiopathology, State University Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Maria Valdrinez Campana Lonardoni
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil
| | - Izabel Galhardo Demarchi
- Graduate Program in Health Sciences, State University of Maringá, Avenida Colombo, 5790, Jardim Universitário, Maringá, 87020-900, PR, Brazil.,Health Sciences Center - Department of Clinical Analysis, Federal University of Santa Catarina, Campus Universitário Reitor João David Ferreira Lima, s/n°, Bairro Trindade, Florianópolis, 88040-900, SC, Brazil
| |
Collapse
|
18
|
Cosco D, Bruno F, Castelli G, Puleio R, Bonacci S, Procopio A, Britti D, Fresta M, Vitale F, Paolino D. Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases. Macromol Biosci 2021; 21:e2100046. [PMID: 34117834 DOI: 10.1002/mabi.202100046] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2021] [Revised: 04/26/2021] [Indexed: 11/08/2022]
Abstract
Leishmaniasis is a human and animal disease endemic in tropical and subtropical areas treated by means of pentavalent antimony as first-line approach. Unfortunately, the formulations available on the market are characterized by significant side effects and a total remission of the disease is difficult to be obtained. The aim of this investigation is to describe the development and characterization of aqueous-core poly-l-lactide (PLA) nanocapsules containing glucantime (meglumine antimoniate, MA) with the aim of increasing the pharmacological efficacy of the active compound. The polymeric systems characterized by a mean diameter of ≈300 nm exert a great interaction with murine macrophages. MA-loaded PLA nanocapsules show a great antileishmanial activity on mice infected with Leishmania infantum with respect to the free drug, favoring a decrease of the administration times. The biodistribution profiles demonstrate a lower renal accumulation of MA after its nanoencapsulation and a significant increase of its plasmatic half-life. The parasite load evaluated by immunohistochemistry shows a significant decrease in liver, spleen, and kidneys when mice are treated with MA-loaded PLA nanocapsules especially after 45 days. The obtained results demonstrate the potential application of MA-loaded PLA nanocapsules as novel nanomedicine for the treatment of leishmaniasis.
Collapse
Affiliation(s)
- Donato Cosco
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Federica Bruno
- Centro di Referenza Nazionale per le Leishmaniosi, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Germano Castelli
- Centro di Referenza Nazionale per le Leishmaniosi, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Roberto Puleio
- Laboratorio Istopatologia e Immunoistochimica, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Sonia Bonacci
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Antonio Procopio
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Domenico Britti
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Massimo Fresta
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| | - Fabrizio Vitale
- Centro di Referenza Nazionale per le Leishmaniosi, Istituto Zooprofilattico Sperimentale della Sicilia A. Mirri, Via G. Marinuzzi 3, Palermo, 90129, Italy
| | - Donatella Paolino
- Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Campus Universitario "S. Venuta,", Catanzaro, I-88100, Italy
| |
Collapse
|
19
|
Leishmanicidal activities of biosynthesized BaCO 3 (witherite) nanoparticles and their biocompatibility with macrophages. Bioprocess Biosyst Eng 2021; 44:1957-1964. [PMID: 33934243 DOI: 10.1007/s00449-021-02576-w] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Accepted: 04/21/2021] [Indexed: 10/21/2022]
Abstract
The aim of this study was cost-effective and greener synthesis of barium carbonate (BaCO3 or witherite) nanoparticles with economic importance, and to evaluate their therapeutic potentials and biocompatibility with immune cells. Barium carbonate nanoparticles were biosynthesized using black elderberry extract in one step with non-toxic precursors and simple laboratory conditions; their morphologies and specific structures were analyzed using field emission scanning electron microscopy with energy dispersive X-ray spectroscopy (FESEM-EDX). The therapeutic capabilities of these nanoparticles on the immune cells of murine macrophages J774 and promastigotes Leishmania tropica were evaluated. BaCO3 nanoparticles with IC50 = 46.6 µg/mL were more effective than negative control and glucantium (positive control) in reducing promastigotes (P < 0.01). Additionally, these nanoparticles with a high value of cytotoxicity concentration 50% (CC50) were less toxic to macrophage cells than glucantime; however, they were significantly different at high concentrations compared to the negative control.
Collapse
|
20
|
Jamshaid H, Din FU, Khan GM. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight. J Nanobiotechnology 2021; 19:106. [PMID: 33858436 PMCID: PMC8051083 DOI: 10.1186/s12951-021-00853-0] [Citation(s) in RCA: 31] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Accepted: 04/07/2021] [Indexed: 12/13/2022] Open
Abstract
As a neglected tropical disease, Leishmaniasis is significantly instigating morbidity and mortality across the globe. Its clinical spectrum varies from ulcerative cutaneous lesions to systemic immersion causing hyperthermic hepato-splenomegaly. Curbing leishmanial parasite is toughly attributable to the myriad obstacles in existing chemotherapy and immunization. Since the 1990s, extensive research has been conducted for ameliorating disease prognosis, by resolving certain obstacles of conventional therapeutics viz. poor efficacy, systemic toxicity, inadequate drug accumulation inside the macrophage, scarce antigenic presentation to body's immune cells, protracted length and cost of the treatment. Mentioned hurdles can be restricted by designing nano-drug delivery system (nano-DDS) of extant anti-leishmanials, phyto-nano-DDS, surface modified-mannosylated and thiolated nano-DDS. Likewise, antigen delivery with co-transportation of suitable adjuvants would be achievable through nano-vaccines. In the past decade, researchers have engineered nano-DDS to improve the safety profile of existing drugs by restricting their release parameters. Polymerically-derived nano-DDS were found as a suitable option for oral delivery as well as SLNs due to pharmacokinetic re-modeling of drugs. Mannosylated nano-DDS have upgraded macrophage internalizing of nanosystem and the entrapped drug, provided with minimal toxicity. Cutaneous Leishmaniasis (CL) was tackling by the utilization of nano-DDS designed for topical delivery including niosomes, liposomes, and transfersomes. Transfersomes, however, appears to be superior for this purpose. The nanotechnology-based solution to prevent parasitic resistance is the use of Thiolated drug-loaded and multiple drugs loaded nano-DDS. These surfaces amended nano-DDS possess augmented IC50 values in comparison to conventional drugs and un-modified nano-DDS. Phyto-nano-DDS, another obscure horizon, have also been evaluated for their anti-leishmanial response, however, more intense assessment is a prerequisite. Impoverished Cytotoxic T-cells response followed by Leishmanial antigen proteins delivery have also been vanquished using nano-adjuvants. The eminence of nano-DDS for curtailment of anti-leishmanial chemotherapy and immunization associated challenges are extensively summed up in this review. This expedited approach is ameliorating the Leishmaniasis management successfully. Alongside, total to partial eradication of this disease can be sought along with associated co-morbidities.
Collapse
Affiliation(s)
- Humzah Jamshaid
- Nanomedicine Research Group, Department of Pharmacy, Quaid-I-Azam University, Islamabad, 45320, Pakistan
| | - Fakhar Ud Din
- Nanomedicine Research Group, Department of Pharmacy, Quaid-I-Azam University, Islamabad, 45320, Pakistan.
| | - Gul Majid Khan
- Nanomedicine Research Group, Department of Pharmacy, Quaid-I-Azam University, Islamabad, 45320, Pakistan.
- Islamia College University, Peshawar, Khyber Pakhtunkhwa, Pakistan.
| |
Collapse
|
21
|
AlMohammed HI, Khudair Khalaf A, E. Albalawi A, Alanazi AD, Baharvand P, Moghaddam A, Mahmoudvand H. Chitosan-Based Nanomaterials as Valuable Sources of Anti-Leishmanial Agents: A Systematic Review. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:689. [PMID: 33801922 PMCID: PMC8000302 DOI: 10.3390/nano11030689] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 03/02/2021] [Accepted: 03/04/2021] [Indexed: 12/25/2022]
Abstract
BACKGROUND The current chemotherapy agents against various forms of leishmaniasis have some problems and side effects, including high toxicity, high cost, and the emergence of resistant strains. Here, we aimed to review the preclinical studies (in vitro and in vivo) on the anti-leishmanial activity of chitosan and chitosan-based particles against Leishmania spp. METHODS This study was conducted based on the 06-PRISMA guidelines and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-Analysis Facility (SyRF) database. Various English databases such as PubMed, Google Scholar, Web of Science, EBSCO, ScienceDirect, and Scopus were used to find the publications related to the anti-leishmanial effects of chitosan and its derivatives and other pharmaceutical formulations, without a date limitation, to find all the published articles. The keywords included "chitosan", "chitosan nanoparticles", "anti-leishmanial", "Leishmania", "leishmaniasis", "cutaneous leishmaniasis", "visceral leishmaniasis", "in vitro", and "in vivo". The language for data collection were limited to English. RESULTS Of 2669 papers, 25 papers, including 7 in vitro (28.0%), 7 in vivo (28.0%), and 11 in vitro/in vivo (44.0%) studies conducted up to 2020 met the inclusion criteria for discussion in this systematic review. The most common species of Leishmania used in these studies were L. major (12, 48.0%), L. donovani (7, 28.0%), and L. amazonensis (4, 16.80%). In vivo, the most used animals were BALB/c mice (11, 61.1%) followed by hamsters (6, 33.3%) and Wistar rats (1, 5.5%), respectively. In vitro, the most used Leishmania form was amastigote (8, 44.4%), followed by promastigote (4, 22.2%), and both forms promastigote/amastigote (6, 33.3%). CONCLUSION According to the literature, different types of drugs based on chitosan and their derivatives demonstrated considerable in vitro and in vivo anti-leishmanial activity against various Leishmania spp. Based on the findings of this review study, chitosan and its derivatives could be considered as an alternative and complementary source of valuable components against leishmaniasis with a high safety index. Nevertheless, more investigations are required to elaborate on this result, mainly in clinical settings.
Collapse
Affiliation(s)
- Hamdan I. AlMohammed
- Department of Microbiology and Parasitology, Almaarefa University, Riyadh 11597, Saudi Arabia;
| | - Amal Khudair Khalaf
- Department of Microbiology, College of Medicine, University of Thiqar, Thiqar 0096442, Iraq;
| | | | - Abdullah D. Alanazi
- Department of Biological Science, Faculty of Science and Humanities, Shaqra University, P.O. Box 1040, Ad-Dawadimi 11911, Saudi Arabia;
- Department of Medical Laboratory, Alghad International Colleges for Applied Medical Science, Tabuk 47913, Saudi Arabia
| | - Parastoo Baharvand
- Department of Social Medicine, School of Medicine, Lorestan University of Medical Sciences, Khorramabad 6813833946, Iran;
| | - Ali Moghaddam
- Student Research Committee, Lorestan University of Medical Sciences, Khorramabad 6813833946, Iran;
| | - Hossein Mahmoudvand
- Nutritional Health Research Center, Lorestan University of Medical Sciences, Khorramabad 6813833946, Iran
| |
Collapse
|
22
|
Cheraghipour K, Masoori L, Ezzatkhah F, Salimikia I, Amiri S, Makenali AS, Taherpour F, Mahmoudvand H. Effect of chitosan on Toxoplasma gondii infection: A systematic review. Parasite Epidemiol Control 2020; 11:e00189. [PMID: 33163635 PMCID: PMC7607504 DOI: 10.1016/j.parepi.2020.e00189] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 10/06/2020] [Accepted: 10/18/2020] [Indexed: 01/24/2023] Open
Abstract
Background The preferred treatment for management of toxoplasmosis is the combined use of pyrimethamine and sulfadiazine. However, there are a wide number of adverse side effects with these medications. Recent research has focused on the use of chitosan for the treatment of Toxoplasma gondii infections. This review was performed to obtain a better understanding of the in vivo and in vitro effects of chitosan on T. gondii strains. Methods The current study was carried out according to the PRISMA guideline and registered in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-analysis Facility (SyRF) database. The search was performed in five scientific databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar, with date limits of 1992 to December 2019. The search was restricted to articles published in the English language. The words and terms searched were "Toxoplasma gondii", "Chitosan", "nanoparticles" and "anti-toxoplasmosis" with AND or OR. Results Of 2500 manuscripts, 9 met the eligibility criteria for review. All studies used the RH strain of T. gondii, with Me49 and PRU each included in one study. Five studies (56%) were performed in vivo, one study in vitro and 3 studies included in vivo and in vitro tests. Conclusion Considering the low toxicity and the high inhibitory potency of chitosan against T. gondii, chitosan nanoparticles show potential as an alternative treatment for T. gondii infections.
Collapse
Affiliation(s)
- Kourosh Cheraghipour
- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Leila Masoori
- Department of Laboratory Sciences, School of Allied Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Fatemeh Ezzatkhah
- Department of Laboratory Sciences, Sirjan School of Medical Sciences, Sirjan, Iran
| | - Iraj Salimikia
- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Sana Amiri
- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | | | - Farshad Taherpour
- Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| | - Hossein Mahmoudvand
- Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
| |
Collapse
|
23
|
Loiseau PM, Pomel S, Croft SL. Chitosan Contribution to Therapeutic and Vaccinal Approaches for the Control of Leishmaniasis. Molecules 2020; 25:E4123. [PMID: 32916994 PMCID: PMC7571104 DOI: 10.3390/molecules25184123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Revised: 09/07/2020] [Accepted: 09/08/2020] [Indexed: 12/11/2022] Open
Abstract
The control of leishmaniases, a complex parasitic disease caused by the protozoan parasite Leishmania, requires continuous innovation at the therapeutic and vaccination levels. Chitosan is a biocompatible polymer administrable via different routes and possessing numerous qualities to be used in the antileishmanial strategies. This review presents recent progress in chitosan research for antileishmanial applications. First data on the mechanism of action of chitosan revealed an optimal in vitro intrinsic activity at acidic pH, high-molecular-weight chitosan being the most efficient form, with an uptake by pinocytosis and an accumulation in the parasitophorous vacuole of Leishmania-infected macrophages. In addition, the immunomodulatory effect of chitosan is an added value both for the treatment of leishmaniasis and the development of innovative vaccines. The advances in chitosan chemistry allows pharmacomodulation on amine groups opening various opportunities for new polymers of different size, and physico-chemical properties adapted to the chosen routes of administration. Different formulations have been studied in experimental leishmaniasis models to cure visceral and cutaneous leishmaniasis, and chitosan can act as a booster through drug combinations with classical drugs, such as amphotericin B. The various architectural possibilities given by chitosan chemistry and pharmaceutical technology pave the way for promising further developments.
Collapse
Affiliation(s)
- Philippe M. Loiseau
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France;
| | - Sébastien Pomel
- Antiparasite Chemotherapy, CNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France;
| | - Simon L. Croft
- Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK;
| |
Collapse
|
24
|
Mubarak SM, Alnomani Y. Synergistic effect of Eucalyptus camaldulensis essential oil with glucantime against cutaneous Leishmaniasis in vitro and in vivo. Meta Gene 2020. [DOI: 10.1016/j.mgene.2020.100717] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
25
|
Chitosan-based particulate systems for drug and vaccine delivery in the treatment and prevention of neglected tropical diseases. Drug Deliv Transl Res 2020; 10:1644-1674. [PMID: 32588282 DOI: 10.1007/s13346-020-00806-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Neglected tropical diseases (NTDs) are a diverse group of infections which are difficult to prevent or control, affecting impoverished communities that are unique to tropical or subtropical regions. In spite of the low number of drugs that are currently used for the treatment of these diseases, progress on new drug discovery and development for NTDs is still very limited. Therefore, strategies on the development of new delivery systems for current drugs have been the main focus of formulators to provide improved efficacy and safety. In recent years, particulate delivery systems at micro- and nanosize, including polymeric micro- and nanoparticles, liposomes, solid lipid nanoparticles, metallic nanoparticles, and nanoemulsions, have been widely investigated in the treatment and control of NTDs. Among these polymers used for the preparation of such systems is chitosan, which is a marine biopolymer obtained from the shells of crustaceans. Chitosan has been investigated as a delivery system due to the versatility of its physicochemical properties as well as bioadhesive and penetration-enhancing properties. Furthermore, chitosan can be also used to improve treatment due to its bioactive properties such as antimicrobial, tissue regeneration, etc. In this review, after giving a brief introduction to neglected diseases and particulate systems developed for the treatment and control of NTDs, the chitosan-based systems will be described in more detail and the recent studies on these systems will be reviewed. Graphical abstract.
Collapse
|
26
|
Saberi S, Zarrabi Z, Saghaie L, Fassihi A, Pestechian N. Synthesis and comparison of anti-Leishmania major activity of antimony and iron complexes of 3-hydroxypyran-4-one and 3-hydroxypyridine-4-one as bi-dentate ligands. JOURNAL OF REPORTS IN PHARMACEUTICAL SCIENCES 2020. [DOI: 10.4103/jrptps.jrptps_64_18] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
27
|
Saleem K, Khursheed Z, Hano C, Anjum I, Anjum S. Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges. NANOMATERIALS (BASEL, SWITZERLAND) 2019; 9:E1749. [PMID: 31818029 PMCID: PMC6955954 DOI: 10.3390/nano9121749] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 12/03/2019] [Accepted: 12/05/2019] [Indexed: 01/19/2023]
Abstract
Leishmaniasis is a widely distributed protozoan vector-born disease affecting almost 350 million people. Initially, chemotherapeutic drugs were employed for leishmania treatment but they had toxic side effects. Various nanotechnology-based techniques and products have emerged as anti-leishmanial drugs, including liposomes, lipid nano-capsules, metal and metallic oxide nanoparticles, polymeric nanoparticles, nanotubes and nanovaccines, due to their unique properties, such as bioavailability, lowered toxicity, targeted drug delivery, and biodegradability. Many new studies have emerged with nanoparticles serving as promising therapeutic agent for anti-leishmanial disease treatment. Liposomal Amphotericin B (AmB) is one of the successful nano-based drugs with high efficacy and negligible toxicity. A new nanovaccine concept has been studied as a carrier for targeted delivery. This review discusses different nanotechnology-based techniques, materials, and their efficacies in leishmaniasis treatment and their futuristic improvements.
Collapse
Affiliation(s)
- Kiran Saleem
- Department of Biotechnology, Kinnaird College for Women, Lahore 54000, Pakistan; (K.S.); (Z.K.); (I.A.)
| | - Zainab Khursheed
- Department of Biotechnology, Kinnaird College for Women, Lahore 54000, Pakistan; (K.S.); (Z.K.); (I.A.)
| | - Christophe Hano
- Laboratoire de Biologie des Ligneux et des Grandes Cultures, INRA USC1328/Université d’Orléans, Chartres 28000, France;
| | - Iram Anjum
- Department of Biotechnology, Kinnaird College for Women, Lahore 54000, Pakistan; (K.S.); (Z.K.); (I.A.)
| | - Sumaira Anjum
- Department of Biotechnology, Kinnaird College for Women, Lahore 54000, Pakistan; (K.S.); (Z.K.); (I.A.)
| |
Collapse
|
28
|
Kaewklin P, Siripatrawan U, Suwanagul A, Lee YS. Active packaging from chitosan-titanium dioxide nanocomposite film for prolonging storage life of tomato fruit. Int J Biol Macromol 2018; 112:523-529. [DOI: 10.1016/j.ijbiomac.2018.01.124] [Citation(s) in RCA: 160] [Impact Index Per Article: 26.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2017] [Revised: 01/12/2018] [Accepted: 01/17/2018] [Indexed: 01/23/2023]
|